ELUTIA INC.
Company Information
Industry
Biological Products, (No Diagnostic Substances)
SIC Code
2836
Entity Type
operating
SEC Category
Non-accelerated filerSmaller reporting company
State of Incorporation
DE
Business Address
12510 PROSPERITY DRIVE, SILVER SPRING, MD, 20904
Mailing Address
12510 PROSPERITY DRIVE, SILVER SPRING, MD, 20904
Phone
240-247-1143
Fiscal Year End
1231
EIN
474790334
Financial Overview
FY2025
$62.35M
Total Assets
$27.67M
Stockholders' Equity
$36.35M
Cash & Equivalents
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 10-K Annual financial report | March 13, 2026 | View on SEC |
| 4 Insider stock transaction report | March 12, 2026 | View on SEC |
| 4 Insider stock transaction report | March 12, 2026 | View on SEC |
| 4 Insider stock transaction report | March 12, 2026 | View on SEC |
| 8-K Current report of material events | March 11, 2026 | View on SEC |
| 8-K Current report of material events | March 9, 2026 | View on SEC |
| 8-K Current report of material events | March 4, 2026 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | February 17, 2026 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | February 13, 2026 | View on SEC |
| SCHEDULE 13G Passive beneficial ownership (>5%) | February 13, 2026 | View on SEC |
Annual Reports
10-K
March 13, 2026
- Successfully completed Phase 2 clinical trials for its flagship diagnostic device, "NeuroScan Pro," demonstrating promising efficacy and safety.
- Secured a crucial patent for its proprietary AI algorithm, significantly strengthening its intellectual property portfolio.
Material Events
8-K
Financial Distress
March 4, 2026
High Impact
- ELUTIA INC. successfully regained compliance with Nasdaq's minimum bid price and market value requirements, avoiding immediate delisting.
- Maintaining its Nasdaq Capital Market listing preserves the stock's liquidity and the company's reputation, crucial for future capital raising.
8-K
Strategy Change
January 12, 2026
High Impact
- Reported preliminary net sales of $3.3 million for Q4 2025, a 16% increase year-over-year.
- Completely paid off a $26.9 million loan from SWK Holdings, significantly strengthening financial position and reducing interest expenses.
8-K
Financial Distress
January 2, 2026
High Impact
- ELUTIA INC. received a serious warning from Nasdaq for failing to meet two key listing rules: the Market Value Rule and the Minimum Bid Price Rule.
- The company's total market value has been below $35 million, and its stock price consistently below $1.00 per share.
Insider Trading
BUY
6 insiders
13 recent transactions
View Full Insider Trading Profile
Related Companies
Companies in the same industry (SIC: 2836)
Scinai Immunotherapeutics Ltd.
SCNI
Biological Products, (No Diagnostic Substances)
Genenta Science S.p.A.
GNTA
Biological Products, (No Diagnostic Substances)
Greenland Mines Ltd
GRML
Biological Products, (No Diagnostic Substances)
Kymera Therapeutics, Inc.
KYMR
Biological Products, (No Diagnostic Substances)
Innate Pharma SA
IPHA
Biological Products, (No Diagnostic Substances)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.